ABL Bio Inc.

KOSDAQ 298380.KQ

ABL Bio Inc. Return on Equity (ROE) for the year ending December 31, 2023: -3.57%

ABL Bio Inc. Return on Equity (ROE) is -3.57% for the year ending December 31, 2023, a -177.40% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

ABL Bio Inc. Return on Equity (ROE) for the year ending December 31, 2022 was 4.62%, a 105.93% change year over year.
ABL Bio Inc. Return on Equity (ROE) for the year ending December 31, 2021 was -77.85%, a -26.93% change year over year.
ABL Bio Inc. Return on Equity (ROE) for the year ending December 31, 2020 was -61.33%, a -118.79% change year over year.
ABL Bio Inc. Return on Equity (ROE) for the year ending December 31, 2019 was -28.03%.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

KOSDAQ: 298380.KQ

ABL Bio Inc.

CEO	Dr. Sang Hoon Lee Ph.D.
IPO Date	Dec. 19, 2018
Location	South Korea
Headquarters	16 Daewangpangyo-Ro 712 Beon-Gil
Employees	102
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. The company is headquartered in Seongnam, South Korea.

Key trends

Past 5 years